Oncolytics Biotech Inc.

NasdaqCM:ONCY Stock Report

Market Cap: US$103.7m

Oncolytics Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:ONCY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
12 Feb 26BuyUS$30,292Patricia S. AndrewsIndividual35,400US$0.86
12 Feb 26BuyUS$21,240Deborah BrownIndividual25,000US$0.85
12 Feb 26BuyUS$8,298Allison HagermanIndividual10,000US$0.83
12 Feb 26BuyUS$10,033Thomas HeinemanIndividual12,132US$0.83
12 Feb 26BuyUS$29,521Jared KellyIndividual35,100US$0.84
12 Feb 26BuyUS$25,338Wayne PisanoIndividual30,000US$0.84
12 Feb 26BuyUS$83,454Bernd SeizingerIndividual100,000US$0.85
12 Feb 26BuyUS$10,104Kirk LookIndividual12,000US$0.84
11 Feb 26BuyUS$25,418Andrew AromandoIndividual29,600US$0.86
16 Jan 26BuyUS$103,770Bernd SeizingerIndividual100,000US$1.04
12 Aug 25BuyUS$20,281Jared KellyIndividual23,500US$0.86
17 Jul 25BuyUS$5,722Allison HagermanIndividual4,600US$1.24
17 Jul 25BuyUS$19,050Thomas HeinemanIndividual15,000US$1.27
16 Jul 25BuyUS$60,062Jared KellyIndividual50,400US$1.19
15 Jul 25BuyUS$30,238Andrew AromandoIndividual25,500US$1.19
15 Jul 25BuyUS$14,976Kirk LookIndividual12,800US$1.17

Insider Trading Volume

Insider Buying: ONCY insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ONCY?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,444,0152.27%
Institutions2,732,1232.54%
General Public102,430,23895.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 39.6%.

Top Shareholders

Top 25 shareholders own 4.02% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.53%
Bernd Seizinger
566,991US$546.6k54.5%no data
0.46%
Wayne Pisano
492,414US$474.7k90.6%no data
0.4%
Morgan Stanley
426,518US$411.2k11.3%no data
0.27%
Kirk Look
287,515US$277.2k80.3%no data
0.26%
Thomas Heineman
282,818US$272.6k81.2%no data
0.24%
Marshall Wace LLP
262,170US$252.7k-19.1%no data
0.24%
Seeds
258,306US$249.0k0%0.05%
0.19%
International Assets Investment Management, LLC
208,150US$200.7k0.6%0.01%
0.17%
Angela Holtham
183,639US$177.0k0%no data
0.16%
The Goldman Sachs Group, Inc.
169,899US$163.8k-18.6%no data
0.14%
Connective Capital Management, LLC
150,340US$144.9k0%0.09%
0.11%
Allison Hagerman
115,059US$110.9k64.7%no data
0.1%
Deborah Brown
109,851US$105.9k29.5%no data
0.1%
Jared Kelly
109,000US$105.1k47.5%no data
0.073%
XTX Markets Limited
78,661US$75.8k0%no data
0.073%
Patricia S. Andrews
78,128US$75.3k82.9%no data
0.067%
Tocqueville Asset Management LP
72,000US$69.4k0%no data
0.065%
Canadian Imperial Bank of Commerce
70,408US$67.9k16.6%no data
0.065%
Franklin Resources, Inc.
69,842US$67.3k0%no data
0.063%
RBC Dominion Securities Inc.
68,311US$65.8k0.11%no data
0.062%
Geode Capital Management, LLC
66,939US$64.5k0%no data
0.051%
Andrew Aromando
55,100US$53.1k116%no data
0.047%
Christophe Degois
50,670US$48.8k0%no data
0.046%
CIBC Private Wealth Advisors, Inc.
50,000US$48.2k0%no data
0.042%
HeadInvest, LLC
44,700US$43.1k0%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/22 10:13
End of Day Share Price 2026/02/20 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncolytics Biotech Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeCantor Fitzgerald Canada Corporation
Wang ChongEdison Investment Research
Patrick TrucchioH.C. Wainwright & Co.